PMID- 25846070
OWN - NLM
STAT- MEDLINE
DCOM- 20161101
LR  - 20220801
IS  - 1867-0687 (Electronic)
VI  - 12
IP  - 1
DP  - 2016 Feb
TI  - Characteristics of respiratory syncytial virus-induced bronchiolitis co-infection 
      with Mycoplasma pneumoniae and add-on therapy with montelukast.
PG  - 88-95
LID - 10.1007/s12519-015-0024-4 [doi]
AB  - BACKGROUND: The influence of Mycoplasma pneumoniae (MP) infection on 
      bronchiolitis remains unclear. Additionally, reports on the efficacies of 
      leukotriene receptor antagonists in the treatment of bronchiolitis have been 
      inconclusive. METHODS: Children with respiratory syncytial virus (RSV)-induced 
      bronchiolitis were divided into two groups: RSV+MP group and RSV group. Each 
      group was randomly divided into two subgroups: one received routine and placebo 
      treatment, while the other received routine and montelukast treatment for 9 
      months. The cumulative numbers of wheezing episodes and recurrent respiratory 
      tract infections were recorded. Blood parameters were determined. RESULTS: 
      Patients in the RSV+MP group exhibited an older average age, fever, more frequent 
      flaky and patchy shadows in chest X-rays, more frequent extrapulmonary 
      manifestations, and longer hospital stays compared with patients in the RSV 
      group. Additionally, higher baseline blood eosinophil counts, eosinophil cationic 
      protein (ECP), total immunoglobulin E (IgE), interleukin (IL)-4, IL-5, 
      IL-4/interferon-gamma ratios, leukotriene (LT) B4, and LTC4, and lower baseline 
      lipoxin A4 (LXA4)/LTB4 ratios were observed in the RSV+MP group compared with the 
      RSV group. Montelukast treatment decreased the cumulative numbers of recurrent 
      wheezing episodes and recurrent respiratory tract infections at 9 and 12 months. 
      This efficacy may be related to the montelukast-induced reductions in peripheral 
      eosinophil counts, ECP and total IgE, as well as the montelukast-dependent 
      recovery in T helper (Th) 1/Th2 balance and LXA4/LTB4 ratios in children with 
      bronchiolitis. CONCLUSIONS: RSV bronchiolitis with MP infection was associated 
      with clinical and laboratory features that differed from those of RSV 
      bronchiolitis without MP infection. Add-on therapy with montelukast for 9 months 
      was beneficial for children with bronchiolitis at 9 and 12 months after the 
      initiation of treatment.
FAU - Wu, Sheng-Hua
AU  - Wu SH
AD  - Department of Pediatrics, First Affiliated Hospital of Nanjing Medical 
      University, 300 Guangzhou Road, Nanjing, 210029, China. kad-yc@163.com.
FAU - Chen, Xiao-Qing
AU  - Chen XQ
AD  - Department of Pediatrics, Jiangsu Maternity and Children Healthcare Hospital, 
      Nanjing, 210036, China.
FAU - Kong, Xia
AU  - Kong X
AD  - Department of Pediatrics, Nanjing First Hospital Affiliated to Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Yin, Pei-Ling
AU  - Yin PL
AD  - Department of Pediatrics, Nanjing First Hospital Affiliated to Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Dong, Ling
AU  - Dong L
AD  - Department of Pediatrics, First Affiliated Hospital of Nanjing Medical 
      University, 300 Guangzhou Road, Nanjing, 210029, China.
FAU - Liao, Pei-Yuan
AU  - Liao PY
AD  - Department of Pediatrics, Central Hospital of Tengzhou, Tengzhou, 277500, China.
FAU - Wu, Jia-Ming
AU  - Wu JM
AD  - Department of Pediatrics, Qidong People's Hospital, 753 Central Jianghai Road, 
      Qidong, 226200, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150406
PL  - Switzerland
TA  - World J Pediatr
JT  - World journal of pediatrics : WJP
JID - 101278599
RN  - 0 (Acetates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/*therapeutic use
MH  - Bronchiolitis/*drug therapy/*virology
MH  - *Coinfection
MH  - Cyclopropanes
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Infant
MH  - Leukotriene Antagonists/*therapeutic use
MH  - Male
MH  - Pneumonia, Mycoplasma/*complications
MH  - Prospective Studies
MH  - Quinolines/*therapeutic use
MH  - Respiratory Syncytial Virus Infections/*complications/*drug therapy
MH  - Sulfides
OTO - NOTNLM
OT  - Mycoplasma pneumoniae
OT  - bronchiolitis
OT  - leukotrienes
OT  - montelukast
OT  - respiratory syncytial virus
EDAT- 2015/04/08 06:00
MHDA- 2016/11/02 06:00
CRDT- 2015/04/08 06:00
PHST- 2014/04/29 00:00 [received]
PHST- 2014/08/26 00:00 [accepted]
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2016/11/02 06:00 [medline]
AID - 10.1007/s12519-015-0024-4 [pii]
AID - 10.1007/s12519-015-0024-4 [doi]
PST - ppublish
SO  - World J Pediatr. 2016 Feb;12(1):88-95. doi: 10.1007/s12519-015-0024-4. Epub 2015 
      Apr 6.